Skip to main content
. Author manuscript; available in PMC: 2022 Sep 5.
Published in final edited form as: Int J Pharm. 2021 Jul 10;606:120877. doi: 10.1016/j.ijpharm.2021.120877

Table 9.

Pharmacokinetic parameters for pure RVT and RVT-NLCs-CP in plasma and breast tissue

Parameters Pharmacokinetics Breast tissue distribution
Pure RVT (p.o) RVT-NLCs-CP (SC) RVT-NLCs-CP (MN) RVT-NLCs-CP (MN)
Cmax (ng/mL) 269.30 ± 30.26 1251.02 ± 93.34 343.75 ± 31.89*+++ 12230.6 ± 1953.45###
Tmax (h) 0.3 ± 0.0 0.25 ± 0.07 2.0 ± 0.0***+++ 6.0 ± 0.0###
t1/2 (h) 3.81± 0.85 1.35 ± 0.06 9.98 ± 0.27** 14.41 ± 1.41##
Ke (1/h) 0.18 ± 0.04 0.52 ± 0.03 0.07 ± 0.002**+++ 0.05 ± 0.005###
AUC0-t (h*ng/mL) 458.3 ± 21.21 3590.65 ± 122.97 4529.2 ± 299.67***+++ 234128.3 ± 42789.86###
AUC0-inf (h*ng/mL) 532.8 ± 79.97 3647.3 ± 122.05 5716.95 ± 396.90***+++ 366075.8 ± 86372.81###
MRT0-t (h) 5.7 ± 0.14 5.55 ± 0.21 15.7 ± 1.48***++ 22.95 ± 2.05###

Statistically significant at

*

p<0.05

**

p<0.01

***

p<0.001 when compared to oral plasma concentration of RVT

+

p<0.05

++

p<0.01

+++

p<0.001 when compared to SC plasma concentration of RVT, and

#

p<0.05

##

p<0.01

###

p<0.001 when compared to MN plasma concentration